FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311453587> ?p ?o ?g. }

• W4311453587 endingPage "49" @default.
• W4311453587 startingPage "42" @default.
• W4311453587 abstract "Anti-tumor necrosis factor-alpha agent (anti-TNF-α) is considered an effective third-line therapy for refractory sarcoidosis,studies observing the efficacy of anti-TNF-α agents show conflicting results.We performed an up-to-date systemic meta-analysis to determine effectiveness and further elucidate the role of anti-TNF-α in the treatment of sarcoidosis.A systematic search was carried out in PubMed/Medline, EMBASE, and Cochrane Library for studies reporting the therapeutic effects of anti-TNF drugs on patients with pulmonary and extra-pulmonary sarcoidosis, published up to April 10, 2022. The study was registered in the international prospective register of systematic reviews (PROSPERO) under ID: CRD42022364614.Clinical trials written reporting the therapeutic effects of anti-TNF drugs on patients with pulmonary and extra-pulmonary sarcoidosis were included.Statistical analyses were performed with Comprehensive Meta-Analysis software, and the random-effects model was used. The combined overall treatment success was determined for patients with pulmonary and extrapulmonary sarcoidosis.Overall treatment success rate wasdefined as no disease progression or improvement in symptoms.Eight clinical trial articles were included in the meta-analysis; four used Infliximab, two Etanercept, one Adalimumab, and one Ustekinumab and Golimumab. The mean age of participants was 48.5 years. The duration of drug therapy ranged from 14 to 45 weeks. We found a combined overall treatment success rate, defined as no disease progression or improvement in symptoms, of 69.9% (95% CI 35.0-90.9, I2: 70%) in the pulmonary sarcoidosis group and 74.5% (95% CI 36.3-93.7, I2: 90%) in the extrapulmonary sarcoidosis group. There was no evidence of publication bias in either group.Treatment of refractory sarcoidosis with anti-TNF-α agents was effective in both pulmonary and extrapulmonary sarcoidosis, with a slightly higher efficacy seen in extrapulmonary sarcoidosis. Further randomized controlled trials should be conducted to determine the effects of anti-TNF-α agents as a part of the management strategy of sarcoidosis. Patients with pulmonary sarcoidosis should be studied separately from patients with extrapulmonary sarcoidosis to adjust for confounding results." @default.
• W4311453587 created "2022-12-26" @default.
• W4311453587 creator A5000067833 @default.
• W4311453587 creator A5005427544 @default.
• W4311453587 creator A5018631336 @default.
• W4311453587 creator A5030313468 @default.
• W4311453587 creator A5045090079 @default.
• W4311453587 creator A5065058000 @default.
• W4311453587 creator A5076325507 @default.
• W4311453587 creator A5089535546 @default.
• W4311453587 date "2023-03-01" @default.
• W4311453587 modified "2023-10-16" @default.
• W4311453587 title "Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis" @default.
• W4311453587 cites W1964435302 @default.
• W4311453587 cites W1988155176 @default.
• W4311453587 cites W1997106678 @default.
• W4311453587 cites W2000894943 @default.
• W4311453587 cites W2016246684 @default.
• W4311453587 cites W2032381017 @default.
• W4311453587 cites W2045831110 @default.
• W4311453587 cites W2057359257 @default.
• W4311453587 cites W2059686064 @default.
• W4311453587 cites W2065893580 @default.
• W4311453587 cites W2076158450 @default.
• W4311453587 cites W2088228080 @default.
• W4311453587 cites W2091054858 @default.
• W4311453587 cites W2111252491 @default.
• W4311453587 cites W2112441575 @default.
• W4311453587 cites W2120099882 @default.
• W4311453587 cites W2122283654 @default.
• W4311453587 cites W2122322821 @default.
• W4311453587 cites W2122408285 @default.
• W4311453587 cites W2122863713 @default.
• W4311453587 cites W2126930838 @default.
• W4311453587 cites W2130860647 @default.
• W4311453587 cites W2131718547 @default.
• W4311453587 cites W2154921150 @default.
• W4311453587 cites W2336449142 @default.
• W4311453587 cites W2555794806 @default.
• W4311453587 cites W2741130337 @default.
• W4311453587 cites W2999794673 @default.
• W4311453587 cites W3015922762 @default.
• W4311453587 cites W3016231288 @default.
• W4311453587 cites W3023241955 @default.
• W4311453587 cites W3044254922 @default.
• W4311453587 cites W3146142859 @default.
• W4311453587 cites W3166756865 @default.
• W4311453587 cites W4210995779 @default.
• W4311453587 cites W4211032738 @default.
• W4311453587 cites W4220874555 @default.
• W4311453587 doi "https://doi.org/10.1016/j.ejim.2022.12.003" @default.
• W4311453587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36526497" @default.
• W4311453587 hasPublicationYear "2023" @default.
• W4311453587 type Work @default.
• W4311453587 citedByCount "0" @default.
• W4311453587 crossrefType "journal-article" @default.
• W4311453587 hasAuthorship W4311453587A5000067833 @default.
• W4311453587 hasAuthorship W4311453587A5005427544 @default.
• W4311453587 hasAuthorship W4311453587A5018631336 @default.
• W4311453587 hasAuthorship W4311453587A5030313468 @default.
• W4311453587 hasAuthorship W4311453587A5045090079 @default.
• W4311453587 hasAuthorship W4311453587A5065058000 @default.
• W4311453587 hasAuthorship W4311453587A5076325507 @default.
• W4311453587 hasAuthorship W4311453587A5089535546 @default.
• W4311453587 hasConcept C126322002 @default.
• W4311453587 hasConcept C143998085 @default.
• W4311453587 hasConcept C17991360 @default.
• W4311453587 hasConcept C2776478404 @default.
• W4311453587 hasConcept C2777138892 @default.
• W4311453587 hasConcept C2777226972 @default.
• W4311453587 hasConcept C2778975655 @default.
• W4311453587 hasConcept C2780132546 @default.
• W4311453587 hasConcept C2781290027 @default.
• W4311453587 hasConcept C2781301800 @default.
• W4311453587 hasConcept C535046627 @default.
• W4311453587 hasConcept C71924100 @default.
• W4311453587 hasConcept C95190672 @default.
• W4311453587 hasConceptScore W4311453587C126322002 @default.
• W4311453587 hasConceptScore W4311453587C143998085 @default.
• W4311453587 hasConceptScore W4311453587C17991360 @default.
• W4311453587 hasConceptScore W4311453587C2776478404 @default.
• W4311453587 hasConceptScore W4311453587C2777138892 @default.
• W4311453587 hasConceptScore W4311453587C2777226972 @default.
• W4311453587 hasConceptScore W4311453587C2778975655 @default.
• W4311453587 hasConceptScore W4311453587C2780132546 @default.
• W4311453587 hasConceptScore W4311453587C2781290027 @default.
• W4311453587 hasConceptScore W4311453587C2781301800 @default.
• W4311453587 hasConceptScore W4311453587C535046627 @default.
• W4311453587 hasConceptScore W4311453587C71924100 @default.
• W4311453587 hasConceptScore W4311453587C95190672 @default.
• W4311453587 hasLocation W43114535871 @default.
• W4311453587 hasLocation W43114535872 @default.
• W4311453587 hasOpenAccess W4311453587 @default.
• W4311453587 hasPrimaryLocation W43114535871 @default.
• W4311453587 hasRelatedWork W1597227996 @default.
• W4311453587 hasRelatedWork W1943494332 @default.
• W4311453587 hasRelatedWork W1979107859 @default.
• W4311453587 hasRelatedWork W2004057177 @default.

• next